M Niemi

Summary

Affiliation: University of Helsinki
Country: Finland

Publications

  1. ncbi request reprint Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone
    Mikko Niemi
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, PO Box 340, FIN 00029 HUS, Helsinki, Finalnd
    Clin Pharmacol Ther 76:239-49. 2004
  2. doi request reprint Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake
    Mikko Niemi
    Department of Clinical Pharmacology, University of Helsinki, PO Box 20, Helsinki, FI 00014, Finland
    Pharmacol Rev 63:157-81. 2011
  3. pmc Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects
    Mikko Niemi
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Br J Clin Pharmacol 56:427-32. 2003
  4. ncbi request reprint Global analysis of genetic variation in SLCO1B1
    Marja K Pasanen
    University of Helsinki, Department of Clinical Pharmacology, Helsinki University Central Hospital, PO Box 340, FIN 00029 HUS, Helsinki, Finland
    Pharmacogenomics 9:19-33. 2008
  5. ncbi request reprint Effect of fluconazole on the pharmacokinetics and pharmacodynamics of nateglinide
    Mikko Niemi
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Finland
    Clin Pharmacol Ther 74:25-31. 2003
  6. doi request reprint Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide
    Annikka Kalliokoski
    Department of Clinical Pharmacology, Helsinki University Central Hospital, FIN 00029 HUS, Finland
    J Clin Pharmacol 48:311-21. 2008
  7. doi request reprint Transporter pharmacogenetics and statin toxicity
    M Niemi
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Clin Pharmacol Ther 87:130-3. 2010
  8. ncbi request reprint Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism
    A Kalliokoski
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Clin Pharmacol Ther 84:488-96. 2008
  9. ncbi request reprint Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride
    M Niemi
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Finland
    Clin Pharmacol Ther 69:194-200. 2001
  10. doi request reprint The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo
    A Tornio
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Clin Pharmacol Ther 84:403-11. 2008

Collaborators

Detail Information

Publications72

  1. ncbi request reprint Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone
    Mikko Niemi
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, PO Box 340, FIN 00029 HUS, Helsinki, Finalnd
    Clin Pharmacol Ther 76:239-49. 2004
    ..Trimethoprim is a relatively selective inhibitor of the cytochrome P450 (CYP) 2C8 enzyme in vitro. Rifampin (INN, rifampicin) is a potent inducer of several CYP enzymes, and in vitro studies have suggested that it also induces CYP2C8...
  2. doi request reprint Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake
    Mikko Niemi
    Department of Clinical Pharmacology, University of Helsinki, PO Box 20, Helsinki, FI 00014, Finland
    Pharmacol Rev 63:157-81. 2011
    ....
  3. pmc Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects
    Mikko Niemi
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Br J Clin Pharmacol 56:427-32. 2003
    ..Our aim was to investigate the effects of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide, a novel short-acting antidiabetic drug...
  4. ncbi request reprint Global analysis of genetic variation in SLCO1B1
    Marja K Pasanen
    University of Helsinki, Department of Clinical Pharmacology, Helsinki University Central Hospital, PO Box 340, FIN 00029 HUS, Helsinki, Finland
    Pharmacogenomics 9:19-33. 2008
    ..The aim of this study was to investigate the diversity of the SLCO1B1 gene at the global level...
  5. ncbi request reprint Effect of fluconazole on the pharmacokinetics and pharmacodynamics of nateglinide
    Mikko Niemi
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Finland
    Clin Pharmacol Ther 74:25-31. 2003
    ..Our aim was to investigate the possible effects of fluconazole on the pharmacokinetics and pharmacodynamics of nateglinide, a new short-acting meglitinide analog antidiabetic drug...
  6. doi request reprint Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide
    Annikka Kalliokoski
    Department of Clinical Pharmacology, Helsinki University Central Hospital, FIN 00029 HUS, Finland
    J Clin Pharmacol 48:311-21. 2008
    ..Thus, in contrast to repaglinide, the disposition of nateglinide is unaffected by the SLCO1B1 c.521T>C polymorphism...
  7. doi request reprint Transporter pharmacogenetics and statin toxicity
    M Niemi
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Clin Pharmacol Ther 87:130-3. 2010
    ..Importantly, the effects of these genetic polymorphisms differ depending on the specific statin that is used. This provides a rational basis for the individualization of lipid-lowering therapy...
  8. ncbi request reprint Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism
    A Kalliokoski
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Clin Pharmacol Ther 84:488-96. 2008
    ..In conclusion, the extent of gemfibrozil-repaglinide interaction depends on SLCO1B1 genotype. Atorvastatin raises plasma repaglinide concentrations, probably by inhibiting organic anion transporting polypeptide 1B1 (OATP1B1)...
  9. ncbi request reprint Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride
    M Niemi
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Finland
    Clin Pharmacol Ther 69:194-200. 2001
    ..Fluvoxamine moderately increased the plasma concentrations and slightly prolonged the elimination half-life of glimepiride...
  10. doi request reprint The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo
    A Tornio
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Clin Pharmacol Ther 84:403-11. 2008
    ..The long-lasting interaction is likely caused by mechanism-based inhibition of CYP2C8 by gemfibrozil glucuronide...
  11. doi request reprint Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast
    T Karonen
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Clin Pharmacol Ther 88:223-30. 2010
    ..0 and 107 micromol/l, respectively). In conclusion, gemfibrozil markedly increases the plasma concentrations of montelukast, indicating that CYP2C8 is crucial in the elimination of montelukast...
  12. doi request reprint ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin
    J E Keskitalo
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Clin Pharmacol Ther 86:197-203. 2009
    ..9 +/- 0.1 vs. 1.1 +/- 0.1). These results indicate that the ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and, even more so, of rosuvastatin-potentially affecting the efficacy and toxicity of statin therapy...
  13. doi request reprint Gemfibrozil is a strong inactivator of CYP2C8 in very small multiple doses
    J Honkalammi
    Department of Clinical Pharmacology, University of Helsinki and HUSLAB, Helsinki University Central Hospital, Helsinki, Finland
    Clin Pharmacol Ther 91:846-55. 2012
    ..Administration of small gemfibrozil doses may be useful in optimizing the pharmacokinetics of CYP2C8 substrate drugs and in reducing the formation of their potentially toxic metabolites via CYP2C8...
  14. ncbi request reprint ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin
    J E Keskitalo
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Clin Pharmacol Ther 84:457-61. 2008
    ..05), but there were no differences between the two genotypes with respect to the pharmacokinetics of the lactones of these drugs...
  15. ncbi request reprint The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide
    M Niemi
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Finland
    Clin Pharmacol Ther 70:58-65. 2001
    ..Concomitant use of clarithromycin or other potent inhibitors of CYP3A4 with repaglinide may enhance its blood glucose-lowering effect and increase the risk of hypoglycemia...
  16. ncbi request reprint Cyclosporine markedly raises the plasma concentrations of repaglinide
    Lauri I Kajosaari
    Department of Clinical Pharmacology, University of Helsinki, and Helsinki University Central Hospital
    Clin Pharmacol Ther 78:388-99. 2005
    ..We studied the effects of cyclosporine (INN, ciclosporin), an inhibitor of CYP3A4 and OATP1B1, on the pharmacokinetics and pharmacodynamics of repaglinide...
  17. ncbi request reprint Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide
    M Niemi
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Finland
    Clin Pharmacol Ther 69:400-6. 2001
    ..It is probable that the blood glucose--lowering effect of glyburide is reduced during concomitant treatment with rifampin. In some patients, the effects of glipizide may also be reduced by rifampin...
  18. ncbi request reprint Gemfibrozil considerably increases the plasma concentrations of rosiglitazone
    M Niemi
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Finland
    Diabetologia 46:1319-23. 2003
    ..Our aim was to investigate possible interaction between gemfibrozil and rosiglitazone, a thiazolidinedione antidiabetic drug...
  19. ncbi request reprint Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone
    Aleksi Tornio
    Department of Clinical Pharmacology, University of Helsinki, Helsinki University Central Hospital, Helsinki, Finland
    Drug Metab Dispos 36:73-80. 2008
    ..Trimethoprim inhibited M-IV formation in vitro (inhibition constant 38.2 muM), predicting the in vivo interaction. In conclusion, drug interactions and pharmacogenetics affecting the CYP2C8 enzyme may change the safety of pioglitazone...
  20. pmc Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide
    Mikko Niemi
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Br J Clin Pharmacol 60:208-17. 2005
    ..Our aim was to investigate the effects of the gemfibrozil-itraconazole combination on the pharmacokinetics and pharmacodynamics of another meglitinide analogue, nateglinide, which is metabolized by CYP2C9 and CYP3A4...
  21. ncbi request reprint Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics
    Mikko Niemi
    Department of Clinical Pharmacology, University of Helsinki University Central Hospital, Helsinki
    Clin Pharmacol Ther 77:468-78. 2005
    ....
  22. doi request reprint Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide
    Annikka Kalliokoski
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Pharmacogenet Genomics 18:937-42. 2008
    ..The aim of this study was to investigate whether the SLCO1B1*1B haplotype affects the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide...
  23. ncbi request reprint Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide
    Mikko Niemi
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Clin Pharmacol Ther 74:380-7. 2003
    ..Our objective was to investigate the effects of genetic polymorphisms of cytochrome P450 (CYP) 2C8 on the pharmacokinetics and pharmacodynamics of the meglitinide analog antidiabetic drug repaglinide...
  24. doi request reprint Mechanism-based inactivation of CYP2C8 by gemfibrozil occurs rapidly in humans
    J Honkalammi
    Department of Clinical Pharmacology, University of Helsinki, Helsinki, Finland
    Clin Pharmacol Ther 89:579-86. 2011
    ..09-fold (0.05-0.14-fold, P < 0.001), respectively. The strong inactivation of CYP2C8, evident as soon as 1 h after gemfibrozil dosing, has implications in clinical practice and in studies with gemfibrozil as a CYP2C8 model inhibitor...
  25. ncbi request reprint Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride
    M Niemi
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Finland
    Clin Pharmacol Ther 70:439-45. 2001
    ..CONCLUSIONS: Gemfibrozil modestly increases the plasma concentrations of glimepiride. This may be caused by inhibition of CYP2C9...
  26. ncbi request reprint Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population
    Marja K Pasanen
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, PO Box 340, Helsinki, 00029 HUS, Finland
    Eur J Clin Pharmacol 62:409-15. 2006
    ....
  27. pmc The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range
    Annikka Kalliokoski
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Br J Clin Pharmacol 66:818-25. 2008
    ..To establish whether the effect of SLCO1B1[encoding organic anion transporting polypeptide 1B1 (OATP1B1)] c.521T-->C (p.Val174Ala) polymorphism on the pharmacokinetics of repaglinide is dose-dependent...
  28. ncbi request reprint Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin
    M K Pasanen
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Clin Pharmacol Ther 82:726-33. 2007
    ..521CC genotype than in those with the c.521TT genotype. These results indicate that, unexpectedly, SLCO1B1 polymorphism has a larger effect on the AUC of atorvastatin than on the more hydrophilic rosuvastatin...
  29. ncbi request reprint Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide
    M Niemi
    Department of Clinical Pharmacology, Helsinki University Central Hospital, P O Box 340, 00029, HUS, Finland
    Diabetologia 46:347-51. 2003
    ..Our aim was to investigate possible interactions of gemfibrozil, itraconazole, and their combination with repaglinide...
  30. ncbi request reprint Rifampicin reduces plasma concentrations of celiprolol
    J J Lilja
    Department of Clinical Pharmacology, University of Helsinki, Haartmaninkatu 4, 00290 Helsinki, Finland
    Eur J Clin Pharmacol 59:819-24. 2004
    ..The beta-adrenoceptor-blocking agent celiprolol undergoes negligible metabolism, but is a substrate for P-glycoprotein. Our objective was to investigate the effects of rifampicin on the pharmacokinetics of celiprolol in healthy subjects...
  31. ncbi request reprint Stereoselective interaction between the CYP2C8 inhibitor gemfibrozil and racemic ibuprofen
    Aleksi Tornio
    Department of Clinical Pharmacology, University of Helsinki, Haartmaninkatu 4, 00290, Helsinki, Finland
    Eur J Clin Pharmacol 63:463-9. 2007
    ..We studied the possible effect of gemfibrozil, an in vivo inhibitor of CYP2C8, on the pharmacokinetics of ibuprofen in healthy volunteers...
  32. ncbi request reprint Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide
    Lauri I Kajosaari
    Department of Clinical Pharmacology, University of Helsinki, and Helsinki University Central Hospital, Helsinki, Finland
    Clin Pharmacol Ther 79:231-42. 2006
    ..We studied the effects of telithromycin, montelukast, and the combination of telithromycin and montelukast on the pharmacokinetics and pharmacodynamics of repaglinide...
  33. pmc The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects
    Mikko Niemi
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Br J Clin Pharmacol 57:441-7. 2004
    ....
  34. ncbi request reprint Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide
    Mikko Niemi
    Department of Clinical Pharmacology, Helsinki University Central Hospital, PO Box 340, FI 00029, HUS, Finland
    Eur J Clin Pharmacol 62:463-72. 2006
    ..Our aim was to investigate the effects of itraconazole, an inhibitor of CYP3A4 and P-glycoprotein, and gemfibrozil, an inhibitor of CYP2C8, on the pharmacokinetics of loperamide...
  35. ncbi request reprint Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes
    Mikko Niemi
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Clin Pharmacol Ther 72:326-32. 2002
    ..Our objective was to investigate the effects of genetic polymorphisms of cytochrome P450 (CYP) 2C9 on the pharmacokinetics of glyburide (INN, glibenclamide) and glimepiride, two widely used sulfonylurea antidiabetic drugs...
  36. pmc No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin
    Jenni E Keskitalo
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki FI 00029, Finland
    Br J Clin Pharmacol 68:207-13. 2009
    ..This study aimed to investigate possible effects of ABCB1 genotype on fluvastatin, pravastatin, lovastatin, and rosuvastatin pharmacokinetics...
  37. pmc No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone
    Annikka Kalliokoski
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Br J Clin Pharmacol 65:78-86. 2008
    ....
  38. doi request reprint Carboxylesterase 1 polymorphism impairs oseltamivir bioactivation in humans
    E K Tarkiainen
    Department of Clinical Pharmacology, University of Helsinki and HUSLAB, Helsinki University Central Hospital, Helsinki, Finland
    Clin Pharmacol Ther 92:68-71. 2012
    ..025) and 23% smaller carboxylate-to-oseltamivir AUC(0-∞) ratio (P = 0.006) than noncarriers (n = 12). This shows that the CES1 c.428G>A polymorphism impairs oseltamivir bioactivation in humans...
  39. pmc Impact of OATP transporters on pharmacokinetics
    A Kalliokoski
    Department of Clinical Pharmacology, University of Helsinki, Helsinki, Finland
    Br J Pharmacol 158:693-705. 2009
    ..This review compiles the current knowledge about the expression and function of human OATP transporters, their substrate and inhibitor specificities, as well as pharmacogenetics...
  40. doi request reprint Grapefruit juice greatly reduces the plasma concentrations of the OATP2B1 and CYP3A4 substrate aliskiren
    T Tapaninen
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Clin Pharmacol Ther 88:339-42. 2010
    ..001), and elimination half-life (t(1/2)) from 26.1 to 23.6 h (P = 0.020). Therefore, concomitant use of aliskiren and grapefruit juice is best avoided...
  41. ncbi request reprint Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole
    Kari Raaska
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Finland
    Clin Pharmacol Ther 72:362-9. 2002
    ..Our objective was to examine the effects of itraconazole on the pharmacokinetics and cortisol-suppressant activity of budesonide administered by inhalation...
  42. ncbi request reprint Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazone
    Tiina Jaakkola
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, P O Box 340, 00029 HUS, Helkinski, Finland
    Eur J Clin Pharmacol 62:503-9. 2006
    ..Our objective was to determine whether montelukast and zafirlukast increase the plasma concentrations of pioglitazone in humans...
  43. doi request reprint Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin
    Jenni E Keskitalo
    Department of Clinical Pharmacology, Helsinki University Central Hospital, Finland
    Pharmacogenomics 10:1617-24. 2009
    ..This study aimed to investigate possible effects of the ABCG2 c.421C>A (p.Gln141Lys; rs2231142) genotype on fluvastatin, pravastatin and simvastatin pharmacokinetics...
  44. doi request reprint Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate
    Marja K Pasanen
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Pharmacogenet Genomics 18:921-6. 2008
    ..In conclusion, the low activity SLCO1B1 c.521CC genotype is associated with an increased cholesterol synthesis rate. The short-term effects of statins on cholesterol homeostasis were not associated with the SLCO1B1 polymorphism...
  45. ncbi request reprint SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid
    Marja K Pasanen
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Pharmacogenet Genomics 16:873-9. 2006
    ..This study aimed to investigate the effects of genetic polymorphism in the SLCO1B1 gene encoding OATP1B1 on the pharmacokinetics of simvastatin...
  46. pmc Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes
    Mia Hedman
    Hospital for Children and Adolescents, University of Helsinki, Helsinki, Finland
    Br J Clin Pharmacol 61:706-15. 2006
    ....
  47. ncbi request reprint Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics
    Mikko Niemi
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Pharmacogenet Genomics 16:801-8. 2006
    ..Our aim was to investigate possible effects of sequence variations in ABCC2, encoding the multidrug resistance-associated protein 2 (MRP2), on the pharmacokinetics of the MRP2 substrate pravastatin...
  48. doi request reprint Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms
    Samuel Fanta
    Department of Clinical Pharmacology, University of Helsinki, and Pediatric Nephrology and Transplantation, Hospital for Children and Adolescents, Helsinki University Central Hospital, Helsinki, Finland
    Pharmacogenet Genomics 18:77-90. 2008
    ....
  49. ncbi request reprint Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance
    Pertti J Neuvonen
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Clin Pharmacol Ther 80:565-81. 2006
    ..Knowledge of the pharmacokinetic and pharmacodynamic properties of lipid-lowering drugs and their interaction mechanisms helps to avoid adverse interactions, without compromising therapeutic benefits...
  50. doi request reprint CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe
    Janne T Backman
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki
    Drug Metab Dispos 37:2359-66. 2009
    ..The estimated CYP2C8 half-life will be useful for in vitro-in vivo extrapolations of drug-drug interactions involving induction or mechanism-based inhibition of CYP2C8...
  51. ncbi request reprint SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin
    Mikko Niemi
    Department of Clinical Pharmacology, University of Helsinki, Helsinki University Central Hospital, Helsinki, Finland
    Clin Pharmacol Ther 80:356-66. 2006
    ..Our aim was to compare the effects of SLCO1B1 polymorphism on the pharmacokinetics of pravastatin and fluvastatin...
  52. doi request reprint Long-term changes in cyclosporine pharmacokinetics after renal transplantation in children: evidence for saturable presystemic metabolism and effect of NR1I2 polymorphism
    Samuel Fanta
    Department of Clinical Pharmacology, Helsinki University Central Hospital, PO Box 705, FI 00029 HUS, Finland
    J Clin Pharmacol 50:581-97. 2010
    ....
  53. doi request reprint Gemfibrozil Impairs Imatinib Absorption and Inhibits the CYP2C8-Mediated Formation of Its Main Metabolite
    A M Filppula
    Department of Clinical Pharmacology, University of Helsinki, Helsinki, Finland
    Clin Pharmacol Ther 94:383-93. 2013
    ..Our findings indicate significant participation of CYP2C8 in the metabolism of imatinib in humans, and support involvement of an intestinal influx transporter in imatinib absorption. ..
  54. doi request reprint Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren
    Tuija Tapaninen
    Department of Clinical Pharmacology, University of Helsinki, Helsinki, Finland
    Eur J Clin Pharmacol 66:497-502. 2010
    ..This study aimed to investigate the effect of rifampicin, an inducer of CYP3A4 and P-glycoprotein, on the pharmacokinetics and pharmacodynamics of aliskiren, a renin inhibitor used in the treatment of hypertension...
  55. doi request reprint Effect of SLCO1B1 polymorphism on the plasma concentrations of bile acids and bile acid synthesis marker in humans
    Xiaoqiang Xiang
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Pharmacogenet Genomics 19:447-57. 2009
    ..Organic anion transporting polypeptide 1B1 (OATP1B1, encoded by SLCO1B1) is a sinusoidal influx transporter of human hepatocytes. Our aim was to characterize the role of OATP1B1 in the hepatic uptake of bile acids in vivo...
  56. doi request reprint Effect of ABCB1 haplotypes on the pharmacokinetics and renin-inhibiting effect of aliskiren
    Tuija Tapaninen
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, PO Box 705, 00029 HUS, Helsinki, Finland
    Eur J Clin Pharmacol 66:865-70. 2010
    ..This study aimed to investigate the possible effects of ABCB1 haplotypes on the pharmacokinetics and renin-inhibiting effect of aliskiren...
  57. ncbi request reprint Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin
    Pertti J Neuvonen
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Clin Pharmacokinet 47:463-74. 2008
    ..On the pharmacokinetic basis, fluvastatin and pravastatin can be better choices than simvastatin or lovastatin for an OTC statin...
  58. pmc Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide
    Jari J Lilja
    Department of Clinical Pharmacology, University of Helsinki, Helsinki, Finland
    Br J Clin Pharmacol 63:732-40. 2007
    ..Our objective was to evaluate whether the P-glycoprotein inhibitor, clarithromycin, increases and the putative OATP2B1 inhibitor, grapefruit juice, decreases plasma concentrations of glibenclamide...
  59. ncbi request reprint The need for treatment and satisfaction with dental appearance among young Finnish adults with and without a history of orthodontic treatment
    H Kerosuo
    Department of Pedodontics and Orthodontics, University of Helsinki, Finland
    J Orofac Orthop 61:330-40. 2000
    ..The high treatment rate in relation to unnoticed treatment need calls for reevaluation of priorities in patient selection...
  60. doi request reprint Role of OATP transporters in the disposition of drugs
    Mikko Niemi
    University of Helsinki, Department of Clinical Pharmacology, Helsinki University Central Hospital, PO Box 340, Helsinki, FIN 00029 HUS, Finland
    Pharmacogenomics 8:787-802. 2007
    ..This article will provide an up-to-date review of human OATPs and their substrates, and a current compilation of their DNA sequence variations...
  61. ncbi request reprint Pharmacokinetic interactions with rifampicin : clinical relevance
    Mikko Niemi
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
    Clin Pharmacokinet 42:819-50. 2003
    ..It is particularly important to remember that the concentrations of many of the other drugs used by the patient will increase when rifampicin is discontinued as the induction starts to wear off...
  62. doi request reprint Itraconazole, a P-glycoprotein and CYP3A4 inhibitor, markedly raises the plasma concentrations and enhances the renin-inhibiting effect of aliskiren
    Tuija Tapaninen
    Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, FI 00029 HUS, Finland
    J Clin Pharmacol 51:359-67. 2011
    ..Concomitant use of aliskiren and itraconazole is best avoided...
  63. ncbi request reprint High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)
    Mikko Niemi
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Pharmacogenetics 14:429-40. 2004
    ..No significant associations were found between OATP-B, MRP2 or MDR1 polymorphisms and the pharmacokinetics of pravastatin. These results suggest that haplotypes are more informative in predicting the OATP-C phenotype than single SNPs...
  64. ncbi request reprint Lipid-lowering response to statins is affected by CYP3A5 polymorphism
    Kari T Kivistö
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Pharmacogenetics 14:523-5. 2004
    ..These findings suggest that CYP3A5 may be a genetic determinant of interindividual differences in response to certain statins...
  65. pmc Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1)
    Mikko Niemi
    Br J Clin Pharmacol 59:602-4. 2005
  66. ncbi request reprint Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin
    Mikko Niemi
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Pharmacogenet Genomics 16:565-8. 2006
    ..However, the present study had sufficient power to detect only a considerably smaller rifampicin-induced increase in 4beta-hydroxycholesterol in carriers of the SLCO1B1 c.521C allele compared to subjects with the reference genotype...
  67. ncbi request reprint Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17
    Mikko Niemi
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Pharmacogenet Genomics 15:303-9. 2005
    ..The aim was to investigate whether polymorphisms in the SLCO1B1 gene, encoding the hepatic uptake transporter OATP1B1, influence the short-term effects of pravastatin on cholesterol synthesis...
  68. ncbi request reprint CYP3A5 genotype is associated with diagnosis of hypertension in elderly patients: data from the DEBATE Study
    Kari T Kivistö
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Am J Pharmacogenomics 5:191-5. 2005
    ..The aim of this study was to address the presently controversial question of whether cytochrome P450 (CYP) 3A5 polymorphism is associated with hypertension...
  69. ncbi request reprint Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin
    Michael Igel
    Department of Clinical Pharmacology, University of Bonn, Bonn, Germany
    Clin Pharmacol Ther 79:419-26. 2006
    ..We have investigated whether this polymorphism influences the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin...
  70. ncbi request reprint Functional interaction of intestinal CYP3A4 and P-glycoprotein
    Kari T Kivistö
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Stuttgart, Germany
    Fundam Clin Pharmacol 18:621-6. 2004
    ..Further understanding this interplay would be potentially useful during drug development to solve bioavailability problems of new drug entities...
  71. ncbi request reprint Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans
    Kari T Kivistö
    Department of Pharmacological Sciences, Medical School, University of Tampere, Tampere 33014, Finland
    Pharm Res 24:239-47. 2007
    ..The possible consequences of drug transporter polymorphisms, especially the SLCO1B1 and ABCC2 polymorphisms, for the lipid-lowering efficacy and tolerability of pravastatin in various ethnic groups warrant further study...
  72. ncbi request reprint Characterisation of cerivastatin as a P-glycoprotein substrate: studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice
    Kari T Kivistö
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, 70376 Stuttgart, Germany
    Naunyn Schmiedebergs Arch Pharmacol 370:124-30. 2004
    ..As several statins are P-glycoprotein substrates, beneficial as well as adverse effects of the statins might be affected by interindividual differences in P-glycoprotein expression or function caused by, e.g., the MDR1 polymorphism...